il15-transpresenting wt1-targeted dendritic cell vaccine
Vaccineexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2023 (NCT05964361)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Wilms tumor proteinImmunity, active
immunity, active - WT1
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05964361 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2023 | Free University of Brussels, Kom Op Tegen Kanker, University of Antwerp |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Free University of Brussels | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Kom Op Tegen Kanker | Academic/Hospital | 1 | 0 | 1 | 2023 |
| University of Antwerp | Academic/Hospital | 1 | 1 | 1 | 2023 |
3 organizations
Page 1 / 1